Zogenix

At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.   We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EMERYVILLE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company's board of directors granted inducement awards to nine (9) new non-executive employees. The awards were made on December 15, 2021, under Zogenix's 2021 Employment Inducement Equity Incentive Award Plan, which was approved by the company's board of directors under Nasdaq Marketplace Rule 5635(c)(4), for granting equity awards to new employees of Zogenix as an inducement to join the company. The awards consist of options to purchase an aggregate of 84,400 shares of Zogenix common stock and 17,300 restricted stock units. The options have a ten year term and an exercise price equal to $13.32 the closing price per share of the common stock on the grant date, and vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee's respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The restricted stock units vest over a four-year period in four equal annual installments beginning on the first anniversary of the vesting commencement date.

Zogenix Reports Granting of Inducement Awards

Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome

Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021

The FDA has granted Priority Review to Zogenix Inc's (NASDAQ: ZGNX) supplemental marketing application seeking approval for Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS) childhood-onset epilepsy. The agency's Prescription Drug User Fee Act (PDUFA) target action date is March 25, 2022.

Why Are Zogenix's Shares Gaining Today?

EMERYVILLE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that members of its management team will participate in fireside chats at two upcoming investor conferences: the Stifel 2021 Virtual Healthcare Conference and Guggenheim Virtual 3rd Annual Neuro/Immunology Conference.

Zogenix to Participate in Two Upcoming Investor Conferences

Coinbase

Novavax

Wall Street projects aggregate sales growth of 509% to 3,324% for these stocks.

4 of the Fastest-Growing Stocks on the Planet Through 2024

Zogenix, Inc. (ZGNX) CEO Dr. Stephen Farr on Q3 2021 Results - Earnings Call Transcript

Zogenix (ZGNX) delivered earnings and revenue surprises of -8.33% and 0.49%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zogenix (ZGNX) Reports Q3 Loss, Tops Revenue Estimates

Zogenix (NASDAQ:ZGNX) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

Recap: Zogenix Q3 Earnings

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Today, we revisit biopharma name Zogenix, Inc. for the first time since early this year.

Zogenix, Inc.: Still Cautiously Optimistic

Zogenix Inc (NASDAQ: ZGNX) has announced interim data from an ongoing 12-month Phase 3 open-label extension (OLE) study of Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS). Data showed that fenfluramine oral solution led to a clinically meaningful and sustained reduction in drop seizures.

Zogenix's Fintepla Shows Long-Term Seizure Frequency Reductions In Childhood Epilepsy

EMERYVILLE, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data from an interim analysis of an on-going 12-month Phase 3 open-label extension (OLE) study (Study 1601; Part 2) showing that treatment with FINTEPLA® (fenfluramine) oral solution led to a clinically meaningful and sustained reduction in drop seizures in patients with Lennox-Gastaut syndrome (LGS) on antiseizure medications (ASMs). LGS is a rare, severe childhood-onset form of epilepsy in which seizures are extremely difficult to control and are associated with significant cognitive, behavioral, and motor disabilities. These data were presented today at the Child Neurology Society (CNS) 2021 Annual Meeting, which is being held September 29 - October 2, 2021.

New FINTEPLA® (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut Syndrome (LGS)

Zogenix (ZGNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zogenix (ZGNX) Moves 6.2% Higher: Will This Strength Last?

Amarin Corporation Plc

Intercept Pharma

Inovio Pharmaceuticals

Plug Power

If these high-water price targets come to fruition, investors will be all smiles.

5 Stocks With 195% to 467% Upside, According to Wall Street

Axsome Therapeutics

COMPASS Pathways

All three stocks on this list can more than double your money according to investment bank analysts who cover them.

3 Biotech Stocks Wall Street Expects to Double Soon

Jazz Pharmaceuticals

Moderna

These fast-paced companies should generate jaw-dropping revenue growth over the next three years.

3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023

Zogenix, Inc. (ZGNX) CEO Dr. Stephen Farr on Q2 2021 Results - Earnings Call Transcript

Zogenix (ZGNX) delivered earnings and revenue surprises of -12.90% and 10.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zogenix (ZGNX) Reports Q2 Loss, Tops Revenue Estimates

Shares of Zogenix (NASDAQ:ZGNX) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 9.38% year over year to ($1.05), which missed the estimate of ($0.94).

Recap: Zogenix Q2 Earnings

EMERYVILLE, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results for the three and six months ended June 30, 2021, and provided a corporate update. The Company will host a conference call today, Thursday, August 5, at 4:30 PM Eastern Time/1:30 PM Pacific Time.

Zogenix Provides Corporate Update and Reports Second Quarter 2021 Financial Results

EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Chief Financial Officer, will participate in a virtual fireside chat on Tuesday, August 10, 2021, at the BofA SMID Cap 2H21 Ideas Conference.

Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference

Bioline RX

BioNTech SE

Canadian Solar

Danaos

Global Ship Lease

Jumia

Goldman Sachs JUST US Large Cap Equity ETF

Lithium Americas Corp

Pfizer

VanEck Rare Earth/Strategic Metals ETF

SSR Mining

Universal Insurance Hlds

Viatris

Today, we have our "Double Down or Diversify" series. We have 13 new ideas that contributors have chosen for the second half of the contest.

2021 Top Idea Contest - New Ideas

Zogenix: Await Q2 Fintepla Revenue, LGS Approval Before Jumping Back In

EMERYVILLE, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups today announced the launch of  VIP Siblings , a new website and suite of materials created to celebrate and deepen support for siblings of adolescents living with rare and severe forms of epilepsy. The spirit of the materials is captured by the slogan “Siblings. Supported.”

VIP Siblings and www.vipsibling.com, New Resources to Support Brothers & Sisters of Those Living with Severe, Rare Epilepsies, Now Available from Zogenix and 10 Advocacy Groups

Zogenix launched its first product, Fintepla, last July and has since beaten analyst expectations in every quarter. Despite that and having a large cash balance, Zogenix stock has remained depressed since the launch.

News for Zogenix Stock (ZGNX)